Vertex Pharmaceuticals' current lineup can treat up to 90% of the 83,000 CF patients in North America, Europe, and Australia. Yet, only 50% of this patient population is being treated.

Shares of Vertex Pharmaceuticals (NASDAQ: ... (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. ... The smart guide to bill consolidation. Food. Food.

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, ... Importantly, suzetrigine met key FDA guidelines for non-opioid analgesics, ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been ...

Vertex Pharmaceuticals Inc.’s $4.9 billion acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company’s rare-disease franchise, analysts said Thursday.

Vertex Pharmaceuticals' experimental cystic-fibrosis treatment met all of its main goals in a late-stage study when tested in patients aged 12 years and older, the company said on Monday.